Human Longevity Stock
Genomics and cell therapy
About Human Longevity Stock
Human Longevity, Inc. (HLI) is the genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived. HLI combines the largest database of genomic and phenotypic data with machine learning to drive discoveries and revolutionize the practice of medicine. HLI’s business areas include the HLI Health Nucleus, a genomic powered clinical research center which uses whole genome sequence analysis, advanced clinical imaging and innovative machine learning, along with curated personal health information, to deliver the most complete picture of individual health; HLIQ™ Whole Genome and HLIQ Oncology.
Investors
Amino Capital
DFJ Growth
Avant, Katerra, Unity Technologies, Collective Health, Sumo Logic, Human Longevity, Outreach, Mapbox, Ring, DataStax
GE Ventures
View, Pivotal, Virgin Hyperloop One, Desktop Metal, Human Longevity, Rethink Robotics, Omada Health, Stem, Sonnen, Catalant
Illumina
OS Fund
StartUp Health
Funding History
| March 2014 | $80.0M |
|---|---|
| April 2016 | $220M |
Management
Co-Founder & CEO
J. Venter
Co-Founder & Vice Chairman
Robert Hariri
Chief Information Officer
Yaron Turpaz
Medical Director
Brad Perkins
Press
Forbes - Feb, 4 2019
Markets Insider - Oct, 3 2018
GenomeWeb - Aug, 31 2018
The San Diego Union-Tribune - Aug, 24 2018
Quartz - Jul, 24 2018
The San Diego Union-Tribune - Jul, 22 2018
- Jan, 27 2017
- Jan, 19 2017
- Jan, 18 2017
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Human Longevity or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
